These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24122760)

  • 21. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).
    Barlesi F; Scherpereel A; Rittmeyer A; Pazzola A; Ferrer Tur N; Kim JH; Ahn MJ; Aerts JG; Gorbunova V; Vikström A; Wong EK; Perez-Moreno P; Mitchell L; Groen HJ
    J Clin Oncol; 2013 Aug; 31(24):3004-11. PubMed ID: 23835708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
    Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
    N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer.
    Urata Y; Okamoto I; Takeda M; Hattori Y; Okuno K; Shimada T; Kurata T; Kaneda H; Miyazaki M; Terashima M; Tanaka K; Morita S; Nakagawa K; Negoro S; Satouchi M
    Cancer; 2013 Jun; 119(12):2275-81. PubMed ID: 23558513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
    Spigel DR; Townley PM; Waterhouse DM; Fang L; Adiguzel I; Huang JE; Karlin DA; Faoro L; Scappaticci FA; Socinski MA
    J Clin Oncol; 2011 Jun; 29(16):2215-22. PubMed ID: 21502556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous non-small cell lung cancer.
    Hata A; Katakami N; Tanaka K; Takeshita J; Matsumoto T; Monden K; Nagata K; Masago K; Kaji R; Fujita S; Tachikawa R; Otsuka K; Otsuka K; Tomii K
    Anticancer Res; 2014 Jan; 34(1):275-81. PubMed ID: 24403474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Glasgow prognostic score as a prognostic factor in patients with advanced non-small cell lung cancer treated with cisplatin-based first-line chemotherapy.
    Jiang AG; Lu HY
    J Chemother; 2015 Feb; 27(1):35-9. PubMed ID: 24716851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
    Scagliotti GV; Vynnychenko I; Park K; Ichinose Y; Kubota K; Blackhall F; Pirker R; Galiulin R; Ciuleanu TE; Sydorenko O; Dediu M; Papai-Szekely Z; Banaclocha NM; McCoy S; Yao B; Hei YJ; Galimi F; Spigel DR
    J Clin Oncol; 2012 Aug; 30(23):2829-36. PubMed ID: 22753922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.
    Mir O; Boudou-Rouquette P; Giroux J; Chapron J; Alexandre J; Gibault L; Ropert S; Coriat R; Durand JP; Burgel PR; Dusser D; Goldwasser F
    Lung Cancer; 2012 Jul; 77(1):104-9. PubMed ID: 22364783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer.
    Claret L; Lu JF; Bruno R; Hsu CP; Hei YJ; Sun YN
    Clin Pharmacol Ther; 2012 Nov; 92(5):631-4. PubMed ID: 22910440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
    Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
    J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.
    Ardizzoni A; Tiseo M; Boni L; Vincent AD; Passalacqua R; Buti S; Amoroso D; Camerini A; Labianca R; Genestreti G; Boni C; Ciuffreda L; Di Costanzo F; de Marinis F; Crinò L; Santo A; Pazzola A; Barbieri F; Zilembo N; Colantonio I; Tibaldi C; Mattioli R; Cafferata MA; Camisa R; Smit EF
    J Clin Oncol; 2012 Dec; 30(36):4501-7. PubMed ID: 23109689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
    Lynch TJ; Patel T; Dreisbach L; McCleod M; Heim WJ; Hermann RC; Paschold E; Iannotti NO; Dakhil S; Gorton S; Pautret V; Weber MR; Woytowitz D
    J Clin Oncol; 2010 Feb; 28(6):911-7. PubMed ID: 20100966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
    J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
    Zhang YF; Chen ZW; Lu S
    Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
    Lee JY; Lim SH; Kim M; Kim S; Jung HA; Chang WJ; Choi MK; Hong JY; Lee SJ; Sun JM; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2014 May; 73(5):1063-70. PubMed ID: 24663503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer.
    Xu B; Liu P; Yin Y; Liu P; Shu Y
    Biomed Pharmacother; 2013 Oct; 67(8):763-9. PubMed ID: 23790249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lower Ras expression as an independent predictor of patient outcomes in lung cancer treated with bevacizumab plus chemotherapy.
    An SJ; Huang YS; Chen ZH; Han JF; Yang JJ; Zhou Q; Xie Z; Yang Y; Yan HH; Wu YL
    Cancer Gene Ther; 2014 Mar; 21(3):110-4. PubMed ID: 24577128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab concomitant with chemotherapy is effective in treating Chinese patients with advanced non-squamous non-small cell lung cancer.
    Sun J; Hu Y; Wu BS; Wang JL; Tao HT; Zhang SJ
    Asian Pac J Cancer Prev; 2014; 15(14):5945-50. PubMed ID: 25081727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy.
    Ying J; Zhou D; Gu T; Huang J; Liu H
    BMC Cancer; 2019 Mar; 19(1):288. PubMed ID: 30925910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
    Addison CL; Ding K; Seymour L; Zhao H; Laurie SA; Shepherd FA; Goss GD; Bradbury PA
    Lung Cancer; 2015 Nov; 90(2):288-95. PubMed ID: 26415995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.